Clinical Trial Search

Primary: Percentage of Participants Who Were Alive and Free From Progressive Disease — 88.28; 76.03 percentage of participants

Primary: Duration of Analgesia — 413.73; 197.35 minutes

Primary: Change in Patient's Satisfaction, Change in Provider's Satisfaction (Mean/SD) — -0.033; 0.032; -0.018; 0.077 units on a scale — p=>0.05

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis — -2.3; -48.2 percent change — p=<0.0001

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis — -50.6; -20.7 percent change — p=<0.0001

Primary: Participants With Adverse Events (AEs). — 851; 30 Participants

Primary: Time to First Clinical Fracture — NA; NA Days — p=<0.0001

Primary: Percentages of Subjects With Human Complement Serum Bactericidal Activity (hSBA) Titers ≥ 1:4, After One Dose Of Either MenACWY-CRM(Ad-) or MenACWY-PS Vaccine In…

Primary: Progression Free Survival (PFS) Per Independent Central Radiology Review — 3.7; 3.6 Months

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs/SAEs Leading to Discontinuation of Study Drug and Deaths Over 12 Treatment Cycles…

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis — -15.6; -47.2 percent change — p=<0.0001

Primary: Change in Body Weight at End of Study Compared to Baseline — 3.29; 0.83 kg

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis — -6.6; -45.7 percent change — p=<0.0001

Primary: Neurological Condition of the Patient — 23; 52; 60; 29 patients

Primary: Overall Recipient Survival at 6-month Post-relapse of Disease — 0; 4 participants